|1.||Rathbone, Michel P: 12 articles (01/2015 - 12/2003)|
|2.||Souza, Diogo O: 12 articles (04/2010 - 04/2004)|
|3.||Jiang, Shucui: 11 articles (02/2013 - 12/2003)|
|4.||Schmidt, André P: 10 articles (04/2010 - 04/2004)|
|5.||Ballerini, Patrizia: 9 articles (01/2015 - 11/2006)|
|6.||Souza, Diogo Onofre: 7 articles (12/2015 - 06/2002)|
|7.||D'Alimonte, Iolanda: 7 articles (01/2015 - 11/2006)|
|8.||Caciagli, Francesco: 7 articles (01/2015 - 12/2003)|
|9.||Ciccarelli, Renata: 6 articles (01/2015 - 12/2003)|
|10.||Rathbone, M P: 6 articles (07/2013 - 01/2000)|
09/01/2014 - "A TLR9 inhibitory oligonucleotide containing five adjacent guanosine residues (G-ODN) exhibited virucidal activity and inhibited HSV-1 replication when added post-infection. "
07/01/2009 - "IDU, TFT) for the treatment of herpes simplex virus (HSV) infections; (vi) acyclic guanosine analogues (e.g. "
04/01/2002 - "Temporal pattern of herpes simplex virus type 1 infection and cell death in the mouse brain stem: influence of guanosine nucleoside analogues."
03/19/1995 - "In the early stage of virus infection, radio-detoxified endotoxin might bind to receptors of immature T cells and facilitate cell cycle through cyclic guanosine 3',5'-monophosphate stimulation. "
09/22/1993 - "The assay involves a heat inactivation step at 56 degrees C to prevent risk of infection, ultrafiltration as a pretreatment step prior to ion-pair reversed-phase liquid chromatography using guanosine as internal standard, and ultraviolet detection at 254 nm. This method has excellent recovery (97-100%), linearity (0.5-100 mg/l) and precision (1.2-8.0% coefficient of variation). "
12/01/2015 - "Guanosine Protects Against Cortical Focal Ischemia. "
01/01/2014 - "Ischemia also affected glutamatergic parameters, illustrated by increased EAAC1 levels and decreased GLT1 levels; guanosine reversed the decreased GLT1 levels and did not affect the EAAC1 levels. "
01/01/2014 - "The potential therapeutic effect of guanosine after cortical focal ischemia in rats."
11/01/2001 - "Male C57 black mice (the "I" group of animals) underwent bilateral renal artery clamp for 32 minutes to induce ischemia and then received either normal saline ("NS") or guanosine ("G"). "
07/01/1993 - "Addition of the permeable analogue of guanosine 3',5'-cyclic monophosphate, 8-bromoguanosine 3',5'-cyclic monophosphate, improved reperfusion-induced intestinal blood flow significantly but did not provide protection against mucosal barrier disruption associated with the first hour of ischemia-reperfusion. "
12/01/1997 - "Reoxygenation of the myocytes after 30 min of anoxia returned guanosine salvage rates to nearly normal (87% of control). "
12/01/1997 - "Anoxia inhibits guanosine salvage in cardiac myocytes."
10/01/1993 - "Hypoxia decreased guanosine 3',5'-cyclic monophosphate (cGMP) content 54 +/- 4% in all LPS and 33 +/- 4% in the non-LPS intact rings (P < 0.05). "
05/01/1992 - "Our laboratory has previously described in isolated 1- to 4-mm calf pulmonary arteries, an endothelium-independent contraction to hypoxia that appears to involve the removal of a H2O2-elicited guanosine 3',5'-cyclic monophosphate (cGMP)-mediated relaxation. "
03/01/1992 - "With 15 min of hypoxia, PA contracted and guanosine 3',5'-cyclic monophosphate content decreased. "
|4.||Melanoma (Melanoma, Malignant)
06/01/1980 - "3. Urinary excretion of guanosine 3':5'-cyclic monophosphate was significantly greater than normal in patients with lymphoid tumours (both sexes) and in male patients with myeloid tumours or malignant melanoma. "
05/28/2008 - "Guanosine promotes B16F10 melanoma cell differentiation through PKC-ERK 1/2 pathway."
02/01/1993 - "The guanosine deletion in B2m gene was detected also in the melanoma tissue from which SK-MEL-33 cells had originated. "
01/01/2014 - "Improving topical non-melanoma skin cancer treatment: In vitro efficacy of a novel guanosine-analog phosphonate."
10/31/2013 - "Our data identify GMPR as a melanoma invasion suppressor and establish a link between guanosine metabolism and Rho-GTPase-dependent melanoma cell invasion. "
|5.||Chronic Hepatitis B
05/01/2006 - "Entecavir, a guanosine analog, has been recently approved in US for the therapy of chronic hepatitis B and its registration is expected soon in Europe. "
10/01/2011 - "We investigated the efficacy of entecavir, a cyclopentyl guanosine nucleoside analogue, as monoprophylaxis in patients with chronic hepatitis B who received a liver transplant. "
12/01/2000 - "Antiviral efficacy of lobucavir (BMS-180194), a cyclobutyl-guanosine nucleoside analogue, in the woodchuck (Marmota monax) model of chronic hepatitis B virus (HBV) infection."
08/01/2008 - "Entecavir is a guanosine nucleoside analogue approved for the treatment of chronic hepatitis B virus (HBV) infection. "
02/01/2008 - "Entecavir, a cyclopentyl guanosine analog, is a potent inhibitor of chronic hepatitis B virus DNA polymerase, inhibiting both the priming and elongation steps of viral DNA replication. "
|2.||DNA (Deoxyribonucleic Acid)
|6.||Glutamic Acid (Glutamate)
|9.||Guanosine Triphosphate (GTP)
|10.||Guanosine Diphosphate (GDP)
|3.||Renal Dialysis (Hemodialysis)
|4.||Highly Active Antiretroviral Therapy (HAART)